查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
皮肤肥大细胞增多症治疗药的全球市场:成长，未来展望，竞争分析(2022年～2030年)
市场调查报告书
商品编码
1149174

皮肤肥大细胞增多症治疗药的全球市场:成长，未来展望，竞争分析(2022年～2030年)

Cutaneous Mastocytosis Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 116 Pages | 商品交期: 最快1-2个工作天内

价格

全球皮肤肥大细胞增多症治疗药的市场规模预测将从2021年的2亿3,027万美金，2022年～2030年的预测期间内预计将以年复合成长率5.6％的速度成长。推动市场的主要因素是提高医生对该病的认识，导致患病率上升，预计这将进一步支持针对皮肤肥大细胞增多症的靶向治疗的研究和开发的增长。

本报告提供全球皮肤肥大细胞增多症治疗药市场相关调查，微·宏观环境分析，市场趋势，竞争资讯，市场区隔分析，波特的五力分析，主要投资市场:技术分析，案例研究，企业简介等资讯提供做着。

目录

第1章 序文

  • 报告的说明
    • 报告的目的
    • 主要读者
    • 主要的产品
  • 市场区隔
  • 调查手法
    • 阶段I - 2次调查
    • 阶段II - 1次调查
    • 阶段III - 专家的检讨
    • 前提条件
    • 所采用的方法

第2章 摘要整理

  • 市场概述:全球皮肤肥大细胞增多症治疗药市场
  • 全球皮肤肥大细胞增多症治疗药市场:各类药物(2021年)
  • 全球皮肤肥大细胞增多症治疗药市场:各地区(2021年)
  • COVID-19影响
  • 富有魅力的投资提案:各地区(2021年)
  • 竞争分析
    • 主要的皮肤肥大细胞增多症治疗药市场供应商的市场定位
    • 皮肤肥大细胞增多症治疗药市场供应商采用的策略
    • 主要的产业策略

第3章 皮肤肥大细胞增多症治疗药市场:商务的预测与市场动态

  • 简介
  • 全球皮肤肥大细胞增多症治疗药市场金额(2020年～2030年)
  • 市场动态
    • 推动市场要素
    • 阻碍市场要素
    • 主要课题
    • 主要的机会
  • 促进因素与阻碍因素的影响分析
  • Seesaw分析
  • 波特的五力分析
  • PESTEL分析

第4章 皮肤肥大细胞增多症治疗药市场:各类药物(2020年～2030年)

  • 市场概要
  • 成长和收益分析:2021年对2030年
  • 市场区隔
    • 抗组织胺药物
    • 皮质类固醇
    • 肥大细胞稳定剂
    • 交感神经刺激药
    • 光化学疗法

第5章 北美的皮肤肥大细胞增多症治疗药市场(2020年～2030年)

  • 市场概要
  • 皮肤肥大细胞增多症治疗药市场:各类药物(2020年～2030年)
  • 皮肤肥大细胞增多症治疗药市场:各地区(2020年～2030年)
    • 北美

第6章 英国·欧洲联盟的皮肤肥大细胞增多症治疗药市场(2020年～2030年)

  • 市场概要
  • 皮肤肥大细胞增多症治疗药市场:各类药物(2020年～2030年)
  • 皮肤肥大细胞增多症治疗药市场:各地区(2020年～2030年)
    • 英国·欧洲联盟

第7章 亚太地区的皮肤肥大细胞增多症治疗药市场(2020年～2030年)

  • 市场概要
  • 皮肤肥大细胞增多症治疗药市场:各类药物(2020年～2030年)
  • 皮肤肥大细胞增多症治疗药市场:各地区(2020年～2030年)
    • 亚太地区

第8章 南美的皮肤肥大细胞增多症治疗药市场(2020年～2030年)

  • 市场概要
  • 皮肤肥大细胞增多症治疗药市场:各类药物(2020年～2030年)
  • 皮肤肥大细胞增多症治疗药市场:各地区(2020年～2030年)
    • 南美

第9章 中东·非洲的皮肤肥大细胞增多症治疗药市场(2020年～2030年)

  • 市场概要
  • 皮肤肥大细胞增多症治疗药市场:各类药物(2020年～2030年)
  • 皮肤肥大细胞增多症治疗药市场:各地区(2020年～2030年)
    • 中东·非洲

第10章 企业简介

  • Pfizer Inc.
  • Merck & Co., Inc.
  • EPI Health, LLC.
  • kaleo, Inc.
  • Bausch Health Companies Inc.
  • Mylan N.V.
  • Sanofi
  • Mallinckrodt
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Johnson & Johnson
Product Code: 138659-08-22

Industry Outlook

Cutaneous mastocytosis treatment market accounted for a market value of US$ 230.27 Mn in 2021 and is projected to grow at a CAGR of 5.6% during the forecast period from 2022 to 2030. Cutaneous mastocytosis is a rare disease in which uncontrolled production of mast cells leads to skin complications such as lesions, blisters, and rashes with aggravated itching. The key causes of cutaneous mastocytosis are a mutation in KIT gene which leads to overproduction of mast cells and excess accumulation of mast cell in the skin leads to chronic as well as acute reactions. The major factors that are driving this market are raising awareness related to the disease in physicians are assisting the growth of prevalence rate and expected to further assist the growth in research & development of target-specific treatment against cutaneous mastocytosis.

Photochemotherapy has satisfactory results and it is becoming choice of treatment for most of the dermatologists in developed as well as developing countries

Photochemotherapy (PUVA) is identified as the fastest growing segment throughout the forecast period from 2022 to 2030 due to an effective combination of drug Psoralens and long-wave ultraviolet radiation to treat cutaneous mastocytosis is accepted and practiced by several dermatologists from developed as well as developing countries. The patients initially exposed to psoralens, drugs that contain chemicals that react with ultraviolet light & later UVA light. However, Photochemotherapy sessions required for a patient suffering from cutaneous mastocytosis are in a range of 10 to 15 times in a month.

Asia Pacific is the fastest growing market due to rising awareness in dermatologists about the rare skin diseases and developing healthcare infrastructure in developing countries

During the forecast period from 2022 to 2030, Asia Pacific identified as the fastest growing cutaneous mastocytosis treatment market mainly due to increasing awareness in dermatologists related to rare genetic disorders, and developing healthcare infrastructure is assisting the diagnosis rate. Significant economic growth in developing & developed countries of Asia Pacific has increased the overall infrastructural development including healthcare, transport, educational, and others. This has led to increasing in opportunities for local as well as migrating individuals due to which population of Caucasians is also increasing in the Asia Pacific and as the study suggests that cutaneous mastocytosis observed mainly in Caucasians.

The key companies currently available in the market are analyzed based on recent market updates, product portfolio, financial data, and major strategies. This report also includes attractive investment proposition analyzed with the help of PESTEL analysis, which focuses on in-depth geographical research. Key companies present in the overall report are Novartis AG, Mylan NV, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Johnson & Johnson, Bayer AG, and Mallinckrodt Pharmaceuticals among others.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Cutaneous Mastocytosis Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Cutaneous Mastocytosis Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

  • Antihistamines
  • Corticosteroids
  • Mast Cell Stabilizers
  • Sympathomimetic Agents (Ephinephrine)
  • Photochemotherapy

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

  • Pre COVID-19 situation
  • Post COVID-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Cutaneous Mastocytosis Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Cutaneous Mastocytosis Treatment market?
  • Which is the largest regional market for Cutaneous Mastocytosis Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Cutaneous Mastocytosis Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Cutaneous Mastocytosis Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Cutaneous Mastocytosis Treatment Market
  • 2.2. Global Cutaneous Mastocytosis Treatment Market, By Drug Class, 2021 (US$ Million)
  • 2.3. Global Cutaneous Mastocytosis Treatment Market, By Geography, 2021 (US$ Million)
  • 2.4. Impact of Covid 19
  • 2.5. Attractive Investment Proposition by Geography, 2021
  • 2.6. Competitive Analysis
    • 2.6.1. Market Positioning of Key Cutaneous Mastocytosis Treatment Market Vendors
    • 2.6.2. Strategies Adopted by Cutaneous Mastocytosis Treatment Market Vendors
    • 2.6.3. Key Industry Strategies

3. Cutaneous Mastocytosis Treatment Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Cutaneous Mastocytosis Treatment Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Cutaneous Mastocytosis Treatment Market: By Drug Class, 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation
    • 4.3.1. Antihistamines
    • 4.3.2. Corticosteroids
    • 4.3.3. Mast Cell Stabilizers
    • 4.3.4. Sympathomimetic Agents (Ephinephrine)
    • 4.3.5. Photochemotherapy

5. North America Cutaneous Mastocytosis Treatment Market, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Cutaneous Mastocytosis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 5.3.Cutaneous Mastocytosis Treatment Market: By Region, 2020-2030, USD (Million)
    • 5.3.1.North America
      • 5.3.1.1. U.S.
      • 5.3.1.2. Canada
      • 5.3.1.3. Rest of North America

6. UK and European Union Cutaneous Mastocytosis Treatment Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Cutaneous Mastocytosis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 6.3.Cutaneous Mastocytosis Treatment Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.UK and European Union
      • 6.3.1.1. UK
      • 6.3.1.2. Germany
      • 6.3.1.3. Spain
      • 6.3.1.4. Italy
      • 6.3.1.5. France
      • 6.3.1.6. Rest of Europe

7. Asia Pacific Cutaneous Mastocytosis Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Cutaneous Mastocytosis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 7.3.Cutaneous Mastocytosis Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.Asia Pacific
      • 7.3.1.1. China
      • 7.3.1.2. Japan
      • 7.3.1.3. India
      • 7.3.1.4. Australia
      • 7.3.1.5. South Korea
      • 7.3.1.6. Rest of Asia Pacific

8. Latin America Cutaneous Mastocytosis Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Cutaneous Mastocytosis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 8.3.Cutaneous Mastocytosis Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Latin America
      • 8.3.1.1. Brazil
      • 8.3.1.2. Mexico
      • 8.3.1.3. Rest of Latin America

9. Middle East and Africa Cutaneous Mastocytosis Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Cutaneous Mastocytosis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 9.3.Cutaneous Mastocytosis Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Middle East and Africa
      • 9.3.1.1. GCC
      • 9.3.1.2. Africa
      • 9.3.1.3. Rest of Middle East and Africa

10. Company Profile

  • 10.1. Pfizer Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Portfolio
    • 10.1.4. Strategic Initiatives
  • 10.2. Merck & Co., Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Portfolio
    • 10.2.4. Strategic Initiatives
  • 10.3. EPI Health, LLC.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Portfolio
    • 10.3.4. Strategic Initiatives
  • 10.4. kaleo, Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Portfolio
    • 10.4.4. Strategic Initiatives
  • 10.5. Bausch Health Companies Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Portfolio
    • 10.5.4. Strategic Initiatives
  • 10.6. Mylan N.V.
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Portfolio
    • 10.6.4. Strategic Initiatives
  • 10.7. Sanofi
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Portfolio
    • 10.7.4. Strategic Initiatives
  • 10.8. Mallinckrodt
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Portfolio
    • 10.8.4. Strategic Initiatives
  • 10.9. Bayer AG
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Portfolio
    • 10.9.4. Strategic Initiatives
  • 10.10. Teva Pharmaceutical Industries Ltd.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Portfolio
    • 10.10.4. Strategic Initiatives
  • 10.11. Novartis AG
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Portfolio
    • 10.11.4. Strategic Initiatives
  • 10.12. Johnson & Johnson
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Portfolio
    • 10.12.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Cutaneous Mastocytosis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 2 North America Cutaneous Mastocytosis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 3 UK and European Union Cutaneous Mastocytosis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 4 Asia Pacific Cutaneous Mastocytosis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 5 Latin America Cutaneous Mastocytosis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 6 Middle East and Africa Cutaneous Mastocytosis Treatment Market By Drug Class, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Cutaneous Mastocytosis Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Cutaneous Mastocytosis Treatment Market: Quality Assurance
  • FIG. 5 Global Cutaneous Mastocytosis Treatment Market, By Drug Class, 2021
  • FIG. 6 Global Cutaneous Mastocytosis Treatment Market, By Geography, 2021
  • FIG. 7 Global Cutaneous Mastocytosis Treatment Market, By Drug Class, 2021 Vs 2030, %
  • FIG. 8 U.S. Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 9 Canada Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 10 Rest of North America Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 11 UK Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 12 Germany Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 13 Spain Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 Italy Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 France Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 Rest of Europe Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 China Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 Japan Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 India Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 Australia Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 South Korea Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 Rest of Asia Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 Brazil Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 Mexico Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Latin America Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 GCC Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Africa Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Middle East and Africa Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030